Axelyf, a biotechnology company focused on RNA therapeutics, has secured $2.6 million in seed financing to further develop its proprietary lipid...
The latest clinical update includes dosing announcements for two trials, with the first patients now treated with Epicrispr Biotechnologies’ EPI-321...
YolTech Therapeutics announced earlier this week that the European Medicines Agency has granted Orphan Drug Designation to YOLT-203, its...
YolTech Therapeutics announced on Monday that the Chinese National Medical Products Administration has approved its IND application for YOLT-101 in...
Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in...
New clinical data from Allogene Therapeutics' Phase 1 TRAVERSE trial reveals durable responses in patients with heavily pre-treated advanced renal...
Prime Medicine has reported promising initial clinical data from the first-ever trial of a prime-editing therapeutic candidate, showing that a single...
This week's clinical update includes FDA RMAT designation to Beam Therapeutics' BEAM-302 for the treatment of alpha-1 antitrypsin deficiency as well...
